Blake Borgeson Biography and Net Worth

Blake Borgeson, Ph.D., a co-founder of the Company, has served as a member of our Board since the company’s founding in November 2013, and served as our Chief Technical Officer from November 2013 to July 2018. Dr. Borgeson earned a B.S. in electrical engineering from Rice University. In February 2016, Dr. Borgeson completed a Ph.D. in bioinformatics at UT Austin in February 2016, using machine learning to exploit new experimental techniques in rapidly mapping protein complexes. Dr. Borgeson has served on the board of the Machine Intelligence Research Institute in Berkeley since September 2018, which focuses on doing foundational mathematical research to ensure smarter-than-human artificial intelligence has a positive impact. Our Board believes Dr. Borgeson is qualified to serve on our Board because of his technical background and his knowledge and perspective of the Company.

What is Blake Borgeson's net worth?: The estimated net worth of Blake Borgeson is at least $43.60 million as of November 12th, 2024. Dr. Borgeson owns 7,066,113 shares of Recursion Pharmaceuticals stock worth more than $43,597,917 as of March 26th. This net worth approximation does not reflect any other investments that Dr. Borgeson may own. Additionally, Dr. Borgeson receives an annual salary of $40,000.00 as Director at Recursion Pharmaceuticals. Learn More about Blake Borgeson's net worth.
How old is Blake Borgeson?: Dr. Borgeson is currently 42 years old. There are 5 older executives and no younger executives at Recursion Pharmaceuticals. The oldest executive at Recursion Pharmaceuticals is Dr. David J. Mauro M.D., Ph.D., Chief Medical Officer, who is 59 years old. Learn More on Blake Borgeson's age.
What is Blake Borgeson's salary?: As the Director of Recursion Pharmaceuticals, Inc., Dr. Borgeson earns $40,000.00 per year. There are 4 executives that earn more than Dr. Borgeson. The highest earning executive at Recursion Pharmaceuticals is Dr. Christopher C. Gibson Ph.D., Co-Founder, CEO & Director, who commands a salary of $806,720.00 per year. Learn More on Blake Borgeson's salary.
How do I contact Blake Borgeson?: The corporate mailing address for Dr. Borgeson and other Recursion Pharmaceuticals executives is 41S RIO GRANDE STREET, SALT LAKE CITY UT, 84101. Recursion Pharmaceuticals can also be reached via phone at 385-269-0203 and via email at investorrelations@recursion.com. Learn More on Blake Borgeson's contact information.
Has Blake Borgeson been buying or selling shares of Recursion Pharmaceuticals?: Blake Borgeson has not been actively trading shares of Recursion Pharmaceuticals during the past quarter. Most recently, Blake Borgeson sold 11,447 shares of the business's stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $7.64, for a transaction totalling $87,455.08. Following the completion of the sale, the director now directly owns 7,066,113 shares of the company's stock, valued at $53,985,103.32. Learn More on Blake Borgeson's trading history.
Who are Recursion Pharmaceuticals' active insiders?: Recursion Pharmaceuticals' insider roster includes Blake Borgeson (Director), Terry-Ann Burrell (Director), Zavain Dar (Director), Christopher Gibson (CEO), Tina Larson (COO), Dean Li (Director), Tina Marriott (President & COO), Michael Secora (CFO), and Shafique Virani (Chief Corporate Development Officer). Learn More on Recursion Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Recursion Pharmaceuticals?: In the last year, insiders at the sold shares 38 times. They sold a total of 632,276 shares worth more than $4,877,731.94. The most recent insider tranaction occured on November, 13th when CFO Michael Secora sold 15,000 shares worth more than $114,900.00. Insiders at Recursion Pharmaceuticals own 15.8% of the company. Learn More about insider trades at Recursion Pharmaceuticals.
Information on this page was last updated on 11/13/2024.

Blake Borgeson Insider Trading History at Recursion Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/12/2024	Sell	11,447	$7.64	$87,455.08	7,066,113
10/29/2024	Sell	11,447	$6.72	$76,923.84	7,077,560
10/15/2024	Sell	11,447	$6.67	$76,351.49	7,089,007
10/1/2024	Sell	11,447	$6.22	$71,200.34	7,098,428
9/17/2024	Sell	11,447	$6.84	$78,297.48	7,109,875
9/3/2024	Sell	11,447	$6.27	$71,772.69	7,121,322
8/20/2024	Sell	11,447	$7.12	$81,502.64	7,132,769
8/6/2024	Sell	11,447	$6.82	$78,068.54	7,144,216
7/23/2024	Sell	11,447	$8.48	$97,070.56	7,155,663
7/9/2024	Sell	11,447	$7.32	$83,792.04	7,167,110
6/25/2024	Sell	11,447	$9.51	$108,860.97	7,177,116
6/11/2024	Sell	11,447	$8.45	$96,727.15	7,188,563
5/28/2024	Sell	11,447	$9.17	$104,968.99	7,186,913
4/30/2024	Sell	11,447	$7.95	$91,003.65	7,218,414
4/16/2024	Sell	11,447	$7.66	$87,684.02	7,229,861
4/2/2024	Sell	11,447	$8.82	$100,962.54	7,241,308
3/19/2024	Sell	20,054	$10.79	$216,382.66	7,252,755
3/5/2024	Sell	20,054	$12.06	$241,851.24	7,272,809
2/20/2024	Sell	20,054	$12.32	$247,065.28	7,292,863
2/6/2024	Sell	11,447	$9.30	$106,457.10	7,312,917
1/23/2024	Sell	20,054	$10.58	$212,171.32	7,324,364
12/26/2023	Sell	20,054	$10.63	$213,174.02	7,364,472
12/12/2023	Sell	11,447	$7.40	$84,707.80	7,384,526
11/28/2023	Sell	11,447	$6.72	$76,923.84	7,395,973
11/14/2023	Sell	8,885	$6.32	$56,153.20	7,407,420
10/31/2023	Sell	8,885	$5.27	$46,823.95	7,416,305
10/17/2023	Sell	8,885	$6.58	$58,463.30	7,425,190
10/3/2023	Sell	8,885	$7.29	$64,771.65	7,434,075
9/19/2023	Sell	8,885	$8.36	$74,278.60	7,442,960
9/5/2023	Sell	8,885	$8.79	$78,099.15	7,451,845
8/22/2023	Sell	8,885	$8.91	$79,165.35	7,460,730
8/8/2023	Sell	17,770	$11.16	$198,313.20	7,469,615
7/25/2023	Sell	18,719	$14.61	$273,484.59	7,487,385
7/11/2023	Sell	8,885	$6.89	$61,217.65	7,520,104
6/27/2023	Sell	8,885	$7.39	$65,660.15	7,528,989
6/13/2023	Sell	15,485	$9.98	$154,540.30	7,525,262
5/30/2023	Sell	8,885	$8.79	$78,099.15	7,540,747
5/16/2023	Sell	8,885	$5.09	$45,224.65	7,549,632
4/18/2023	Sell	8,885	$5.93	$52,688.05	7,558,517
4/4/2023	Sell	8,885	$6.53	$58,019.05	7,567,402
3/21/2023	Sell	8,885	$7.40	$65,749.00	7,576,287
3/7/2023	Sell	8,885	$8.33	$74,012.05	7,585,172
2/21/2023	Sell	8,885	$7.73	$68,681.05	7,594,057
2/7/2023	Sell	8,885	$8.81	$78,276.85	7,602,942
1/24/2023	Sell	8,885	$8.71	$77,388.35	7,611,827
1/10/2023	Sell	8,885	$7.69	$68,325.65	7,620,712
12/27/2022	Sell	8,885	$7.25	$64,416.25	7,628,272
12/13/2022	Sell	8,885	$8.96	$79,609.60	7,637,157
11/29/2022	Sell	8,885	$8.75	$77,743.75	7,646,042
11/16/2022	Sell	17,770	$11.12	$197,602.40	7,654,927
1/4/2022	Sell	9,625	$18.03	$173,538.75
12/21/2021	Sell	9,625	$18.75	$180,468.75
12/7/2021	Sell	9,625	$20.32	$195,580.00

See Full Table

Blake Borgeson Buying and Selling Activity at Recursion Pharmaceuticals

Recursion Pharmaceuticals Company Overview

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Today's Range

Now: $6.17

$6.08

$6.54

50 Day Range

MA: $7.47

$5.94

$10.87

2 Week Range

Now: $6.17

$5.60

$12.36

Volume

14,922,704 shs

Average Volume

10,594,834 shs

Market Capitalization

$2.48 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.85

Blake Borgeson Biography and Net Worth

What is Blake Borgeson's net worth?

How old is Blake Borgeson?

What is Blake Borgeson's salary?

How do I contact Blake Borgeson?

Has Blake Borgeson been buying or selling shares of Recursion Pharmaceuticals?

Who are Recursion Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Recursion Pharmaceuticals?